Sing Yeung Frankie Mak

Title: Sing Yeung Frankie Mak: Innovator in Quinoline Compounds

Introduction

Sing Yeung Frankie Mak is a notable inventor based in Singapore, SG. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on quinoline compounds. His research focuses on developing compounds that can inhibit the Enhancer of Zeste Homolog 2 (EZH2), which plays a crucial role in various diseases.

Latest Patents

Frankie Mak holds a patent for quinoline compounds and compositions aimed at inhibiting EZH2. The invention disclosed relates to aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use for treating diseases or conditions mediated by EZH2 and the Polycomb Repressive Complex (PRC). This patent highlights his commitment to advancing medical science and improving treatment options.

Career Highlights

Frankie Mak is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to collaborate with other experts in the field and contribute to groundbreaking research. His dedication to innovation is evident in his patent and ongoing projects.

Collaborations

Frankie Mak works alongside Xuan Dai, contributing to a collaborative environment that fosters innovation and research excellence.

Conclusion

Sing Yeung Frankie Mak is a distinguished inventor whose work on quinoline compounds has the potential to impact the treatment of various diseases. His contributions to the pharmaceutical industry exemplify the importance of innovation in healthcare.